Business
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in November 2022 and its plans to host an Investor R&D Day in December 2022.\n\n \n \n \n \n \n \n\n \nJefferies London Healthcare Conference\nTuesday, November 15th, 2022 at 5:00pm GMT // 12:00pm ET\nFireside chat with Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences, hosted by Maury Raycroft Ph.D. Equity Research AnalystStifel Healthcare Conference\nWednesday, November 16, 2022 at 8:00am ET\nFireside chat with Paul Stone, Chief Financial Officer, IDEAYA Biosciences, hosted by Ben Burnett, Ph.D. Vice President, Equity AnalystIDEAYA Biosciences Investor R&D Day\nMonday, December 12, 2022 at 8:00am ET\nIDEAYA will host an Investor R&D Day webcast showcasing highlights and insights across its clinical and preclinical pipeline programs, with participation of key opinion leadersPre-registration is available through the following link https://lifescievents.com/event/ideaya-rd-day/ or alternatively, through IDEAYA's investor relations events page at https://ir.ideayabio.com/eventsA live audio webcast of conference events, as permitted by conference host, and of the Investor R&D Day webcast will be available at the \"Investors/News and Events/Investor Calendar\" section of the IDEAYA website at https://ir.ideayabio.com/events. A replay of available webcasts will be accessible for 30 days following the live event.\nAbout IDEAYA Biosciences\nIDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. \nForward-Looking Statements\nThis press release contains forward-looking statements, including, but not limited to, statements related to participation in...